

UK BIOPHARMA LTD

**Company Registration Number:
08148167 (England and Wales)**

Unaudited statutory accounts for the year ended 31 July 2017

Period of accounts

Start date: 01 August 2016

End date: 31 July 2017

UK BIOPHARMA LTD

Contents of the Financial Statements

for the Period Ended 31 July 2017

[Company Information - 3](#)

[Balance sheet - 4](#)

[Additional notes - 6](#)

[Balance sheet notes - 7](#)

UK BIOPHARMA LTD**Company Information**

for the Period Ended 31 July 2017

Director:	Dr G.Chobanyan
Registered office:	1 Primrose Avenue Wolverhampton WV10 8AW
Company Registration Number:	08148167 (England and Wales)

UK BIOPHARMA LTD**Balance sheet**

As at 31 July 2017

	<i>Notes</i>	<i>2017</i> £	<i>2016</i> £
Fixed assets			
Tangible assets:	2	10,008	12,510
Total fixed assets:		10,008	12,510
Current assets			
Debtors:	3	258	400
Cash at bank and in hand:		50	1,414
Total current assets:		308	1,814
Creditors: amounts falling due within one year:	4	(22,020)	(19,708)

Net current assets (liabilities):		<u>(21,712)</u>	<u>(17,894)</u>
Total assets less current liabilities:		(11,704)	(5,384)
Creditors: amounts falling due after more than one year:	5	(13,301)	(15,856)
Total net assets (liabilities):		<u>(25,005)</u>	<u>(21,240)</u>

The notes form part of these financial statements

Page 4

UK BIOPHARMA LTD

Balance sheet continued

As at 31 July 2017

	<i>Notes</i>	<i>2017</i> £	<i>2016</i> £
Capital and reserves			
Called up share capital:		100	100
Profit and loss account:		(25,105)	(21,340)
Shareholders funds:		<u>(25,005)</u>	<u>(21,240)</u>

For the year ending 31 July 2017 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 21 August 2017

And Signed On Behalf Of The Board By:

Name: Dr G.Chobanyan

Status: Director

The notes form part of these financial statements

UK BIOPHARMA LTD

Notes to the Financial Statements

for the Period Ended 31 July 2017

1. Accounting policies

Basis of measurement and preparation

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

Turnover policy

The turnover shown in the profit and loss account represents revenue earned during the period, exclusive of VAT.

Tangible fixed assets depreciation policy

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life. Plant and Machinery, Office equipment , Motor vehicles- 20% reducing balance

Intangible fixed assets amortisation policy

Intangible fixed assets (including purchased goodwill and patents) are amortised at rates calculated to write off the assets on a straight basis over their estimated useful economic lives, not to exceed twenty years. Impairment of intangible assets is only reviewed where circumstances indicate that the carrying value of an asset may not be fully recoverable.

Valuation information and policy

Stocks and work -in-progress are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items. Cost includes all direct expenditure and an appropriate proportion of fixed and variable overheads.

Other accounting policies

Assets obtained under hire purchase contracts or finance leases are capitalised in the balance sheet. Those held under hire purchase contracts are depreciated over their estimated useful lives. Those held under finance leases are depreciated over their estimated useful lives or the lease term, whichever is the shorter. The interest element of these obligations is charged to the profit and loss account over the relevant period. The capital element of the future payments is treated as a liability. Rentals paid under operating leases are charged to the profit and loss account on a straight line basis over the period of the lease. Research and Development Expenditure on research and development is written off in the year in which it is incurred.

UK BIOPHARMA LTD

Notes to the Financial Statements

for the Period Ended 31 July 2017

2. Tangible assets

Page 6

	Plant & machinery	Fixtures & fittings	Office equipment	Motor vehicles	Total
Cost	£	£	£	£	£
At 01 August 2016	360	249	983	14,215	15,807
Additions	-	-	-	-	-
Disposals	-	-	-	-	-
Revaluations	-	-	-	-	-
Transfers	-	-	-	-	-
At 31 July 2017	360	249	983	14,215	15,807
Depreciation					
At 01 August 2016	176	58	580	2,483	3,297
Charge for year	37	38	81	2,346	2,502
On disposals	-	-	-	-	-
Other adjustments	-	-	-	-	-
At 31 July 2017	213	96	661	4,829	5,799
Net book value					
At 31 July 2017	147	153	322	9,386	10,008
At 31 July 2016	184	191	403	11,732	12,510

Page 7
UK BIOPHARMA LTD

Notes to the Financial Statements

for the Period Ended 31 July 2017

3. Debtors

	2017	2016
	£	£
Prepayments and accrued income	258	400

Total

258	400
------------	------------

UK BIOPHARMA LTD**Notes to the Financial Statements**

for the Period Ended 31 July 2017

4.Creditors: amounts falling due within one year note

	2017	2016
	£	£
Bank loans and overdrafts	398	231
Amounts due under finance leases and hire purchase contracts	3,362	4,170
Other creditors	18,260	15,307
Total	<u>22,020</u>	<u>19,708</u>

UK BIOPHARMA LTD**Notes to the Financial Statements**

for the Period Ended 31 July 2017

5.Creditors: amounts falling due after more than one year

	2017	2016
	£	£
Amounts due under finance leases and hire purchase contracts	7,301	9,856
Other creditors	6,000	6,000
Total	<u>13,301</u>	<u>15,856</u>